SCHEMBL26617246

SCHEMBL26617246

O=C(NCc1cccc[n+]1[O-])c1cccc(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 2/20 0.51
▸ TP53 P04637 1/20 0.47
▸ BCL2L1 Q07817 1/20 0.46
▸ MCL1 Q07820 1/20 0.46
▸ NR1H4 Q96RI1 1/20 0.46
▸ AURKA O14965 1/20 0.44
▸ HDAC2 Q92769 1/20 0.43
▸ TACR1 P25103 1/20 0.43
▸ KDM1A O60341 2/20 0.43
▸ HDAC1 Q13547 2/20 0.43
▸ SENP1 Q9P0U3 1/20 0.43
▸ CHRM3 P20309 1/20 0.42
▸ MRGPRX4 Q96LA9 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ CFD P00746 1/20 0.42
▸ DHODH Q02127 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26617234 0.92 TP53 (0.54) EPHX2TP53NR1H4TACR1CHRM3
SCHEMBL26617230 0.89 NR1H4 (0.46) EPHX2NR1H4SENP1CFDDHODH
SCHEMBL26617213 0.89 EPHX2 (0.56) EPHX2NR1H4AURKAHDAC2HDAC1
SCHEMBL31714575 0.88 EPHX2 (0.45) EPHX2NR1H4HDAC2HDAC1SENP1
SCHEMBL26617233 0.88 EPHX2 (0.45) EPHX2NR1H4HDAC2HDAC1SENP1
SCHEMBL26617227 0.88 AURKA (0.49) EPHX2BCL2L1MCL1NR1H4AURKA
SCHEMBL26617250 0.88 TP53 (0.44) EPHX2TP53NR1H4AURKATACR1
SCHEMBL26704136 0.86 MEN1 (0.50) EPHX2NR1H4AURKASENP1CFD
SCHEMBL26617216 0.86 EPHX2 (0.49) EPHX2NR1H4SENP1POLBCFD
SCHEMBL26617226 0.86 EPHX2 (0.48) EPHX2TP53NR1H4AURKATACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-30 — — US claimed
EP-4514777-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-03-05 — — EP claimed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO claimed
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-30 — — US disclosed
EP-4514777-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-03-05 — — EP disclosed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO disclosed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SCNN1B, SCN1B, SCN2B EPHX2 1625/4885TP53 4664/4885BCL2L1 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback